Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) which is shown superiority more than imatinib in first-line treatment for sufferers of CML. [2]. Nilotinib (AMN107) is normally a fresh BCR/ABL inhibitor and it is extremely selective for ABL kinase and 30-flip stronger than imatinib. Nilotinib provides created hematological and cytogenetic replies… Continue reading Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia